Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 6—June 2024
Research

SARS-CoV-2 Disease Severity and Cycle Threshold Values in Children Infected during Pre-Delta, Delta, and Omicron Periods, Colorado, USA, 2021–2022

Laura BankersComments to Author , Shannon C. O’Brien, Diana M. Tapay, Erin Ho, Isaac Armistead, Alexis Burakoff, Samuel R. Dominguez, and Shannon R. Matzinger
Author affiliations: Colorado Department of Public Health and Environment, Denver, Colorado, USA (L. Bankers, S.C. O’Brien, D.M. Tapay, I. Armistead, A. Burakoff, S.R. Matzinger); University of Colorado, Aurora, Colorado, USA (E. Ho, S.R. Dominguez); Children’s Hospital Colorado, Aurora (E. Ho, S.R. Dominguez)

Main Article

Table 1

Descriptive characteristics of 2,299 children with positive SARS-CoV-2 tests during pre-Delta, Delta, and Omicron periods, Colorado, USA, January 2021–January 2022*

Characteristic Total Pre-Delta period Delta period Omicron period p value†
Total population
 2,299
 429 (18.7, 17.1–20.3)
 752 (32.7, 30.8–34.7)
 543 (23.6, 21.9–25.4)
Sex
F 923 (40.1, 38.1–42.2) 215 (50.1, 45.3–55.0) 352 (46.8, 43.2–50.5) 185 (34.1, 30.1–38.2) 0.44
M
 945 (41.1, 39.1–43.2)
 198 (46.2, 41.4–51.0)
 373 (49.6, 46.0–53.2)
 200 (36.8, 32.8–41.0)
Median age, y (range)
 6.5 (0–21)
 6.5 (0–20.2)
 6.0 (0–21)
 6.3 (0–20.9)
Racial/ethnic group
Hispanic 560 (24.4, 22.6–26.2) 131 (30.5, 26.2–35.1) 212 (28.2, 25.0–31.6) 127 (23.4, 19.9–27.2)
Non-Hispanic White 750 (32.6, 30.7–34.6) 203 (47.3, 42.5–52.2) 307 (40.8, 37.3–44.4) 134 (24.7, 21.1–28.5) <0.0001
Non-Hispanic Black 135 (5.9, 5.0–6.9) 19 (4.4, 2.7–6.8) 58 (7.7, 5.9–9.9) 32 (5.9, 4.1–8.2)
Non-Hispanic Asian 43 (1.9, 1.4–2.5) 9 (2.1, 1.0–3.9) 17 (2.3, 1.3–3.6) 10 (1.8, 0.9–3.4)
Unknown‡
 673 (29.3, 27.4–31.2)
 40 (9.3, 6.7–12.5)
 97 (12.9, 10.6–15.5)
 213 (39.2, 35.1–43.5)
Hospitalization status
Outpatient 1,629 (70.9, 69.0–72.7) 261 (60.8, 56.0–65.5) 619 (82.3, 79.4–85.0) 233 (42.9, 38.7–47.2) <0.0001
Inpatient
 670 (29.1, 27.3–31.1)
 168 (39.2, 34.5–44.0)
 133 (17.7, 15.0–20.6)
 310 (57.1, 52.8–61.3)
Any comorbidity, inpatient only§
 383 (57.2, 53.3–61.0)
 101 (60.1, 52.3–67.6)
 74 (55.6, 46.8–64.3)
 173 (55.8, 50.1–61.4)
 0.62
Median time from symptom onset to testing, d (range)
 2 (–29 to 320)
 2 (–1 to 57)
 2 (–2 to 320)
 2 (–29 to 44)
Patients with confirmed sequence 1,177 (51.2, 49.1–53.3) 189 (16.1, 14.0–18.3) 654 (55.6, 52.7–58.4) 334 (28.4, 25.8–31.1)

*Values are no. (%, 95% CI) except as indicated. p values are indicated as appropriate. †p values were obtained from χ2 test of patient characteristics across the 3 variant periods. ‡Unknown racial/ethnic group includes persons with unknown, unknown or not reported, or missing race or ethnicity variables. §Any comorbidity includes history of cardiac, respiratory, gastrointestinal/liver, neurologic, oncologic, obesity, chronic kidney disease, diabetes, or other comorbid condition.

Main Article

Page created: April 08, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external